5-MeO-MsBT
5-MeO-MsBT, also known as 5-methoxy-N-methyl-N-''sec''-butyltryptamine, is a psychedelic drug of the tryptamine and 5-methoxytryptamine families. It emerged as a novel designer drug online in December 2022. More specifically, its chemical synthesis and the claimed properties and effects of 5-MeO-MsBT were posted on a specialized psychoactive drug forum.
The dose of the drug is said to be 10 to 30mg orally and its duration is said to be 3 to 4hours. Its effects were reported to include a tryptamine-like warmth or fuzzy feeling, tactile and music enhancement, enhanced mood, confusion, mild paranoia, weak psychedelic effects and self-detachment at higher doses, and an antidepressant-like psychedelic afterglow. The afterglow is said to last 12 to 24hours, with apparent tolerance developing to it with repeated administration over a few days. 5-MeO-MsBT's effects were described as very similar to those of 5-MeO-MiPT at lower doses, but it is less potent than 5-MeO-MiPT and was regarded as inferior in many respects.
The drug has not otherwise been encountered, for instance sold online or in drug seizures, as of 2023. It is not a controlled substance in Canada as of 2025. The drug is not an explicitly controlled substance in the United States, but could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.